Brief: Synact To Report About Phase IIA Of AP1189 In Q2 2020, Not Q1

SynAct Pharma AB

07/02/2020 08:40

Feb 7 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * WILL REPORT INTERIM DATA FROM ONGOING PHASE IIA STUDY OF
AP1189
IN PATIENTS WITH RHEUMATOID ARTHRITIS IN Q2 2020, NOT IN Q1 2020
AS PREVIOUSLY EXPECTED
    * REPORTING OF TOPLINE RESULT STILL EXPECTED DURING Q1 2021

Source text for Eikon:  ID:nWkrbCNbW3 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))